Guilarte López-Mañas J, Valenzuela Barranco M, Caballero Plasencia A M, Martín Ruiz J L
Servicio de Digestivo, Hospital Universitario San Cecilio, Granada.
Gastroenterol Hepatol. 1998 May;21(5):212-7.
Zinc acexamate (ZAM) is an antiulcer agent with antisecretory and gastroprotective properties. The aim of this study was to evaluate endoscopically and morphometrically the efficacy of ZAM in the prophylaxis of gastroduodenal lesions induced by pyroxicam. Thirty nine patients from 30 to 70 years of age diagnosed with osteoarthritis without lesions in the upper digestive tract on basal endoscopy were studied. A randomized, double blind study was designed in which the patients received 20 mg/day of pyroxicam together with 300 mg/day of ZAM or placebo for 4 weeks. Clinical controls were undertaken on days 0, 14, 28 and endoscopic and histologic controls performed on days 0 and 28. The two groups were homogeneous regarding basal parameters. Endoscopic grading of the gastroduodenal lesions at the end of the study was lower in the group treated with ZAM (p < 0.001). Ulcers were found in only 2 patients (one antral and one duodenal) both of whom were in the placebo group (10.5%). Histologic scoring following treatment demonstrated higher values in the placebo group (p < 0.001) and scarce alterations with respect to base values in the group treated with ZAM. Morphometric quantification showed lower cell densities in both groups at the body level (p < 0.001). However, these did not vary in the antrum in the group treated with ZAM but increased in the placebo group (p < 0.001) as an expression of proliferative cell response to mucosal damage. At a single nightly dosis of 300 mg ZAM is effective in the prophylaxis of gastric and duodenal lesions induced by pyroxicam.
醋氨己酸锌(ZAM)是一种具有抗分泌和胃保护特性的抗溃疡药物。本研究旨在通过内镜检查和形态计量学评估ZAM预防吡罗昔康诱发的胃十二指肠病变的疗效。研究对象为39例年龄在30至70岁之间、经基础内镜检查诊断为骨关节炎且上消化道无病变的患者。设计了一项随机双盲研究,患者接受20mg/天的吡罗昔康加300mg/天的ZAM或安慰剂治疗4周。在第0、14、28天进行临床对照,在第0和28天进行内镜和组织学对照。两组在基础参数方面具有同质性。研究结束时,ZAM治疗组胃十二指肠病变的内镜分级较低(p<0.001)。仅在2例患者中发现溃疡(1例胃窦部溃疡和1例十二指肠溃疡),这2例均在安慰剂组(10.5%)。治疗后的组织学评分显示安慰剂组较高(p<0.001),而ZAM治疗组相对于基础值仅有轻微改变。形态计量学定量显示两组在胃体部的细胞密度均较低(p<0.001)。然而,ZAM治疗组胃窦部的细胞密度没有变化,而安慰剂组增加(p<0.001),这是增殖性细胞对黏膜损伤反应的表现。每晚单次服用300mg ZAM可有效预防吡罗昔康诱发的胃和十二指肠病变。